From: A simulation tool for better management of retinal services
Monthly averages | Current Service | Virtual Clinic + no change in current service | Treat and Extend + no virtual clinic | Virtual Clinic + Treat and Extend | % change |
---|---|---|---|---|---|
New attendances | 119 | 119 | 119 | 119 | 0% |
Follow-ups | 726 | 642 | 812 | 708 | −2% |
Clinic session utilisation | 71% | 64% | 85% | 71% | 0% |
Nurse utilisation | 71% | 65% | 82% | 70% | −1% |
Consultation room utilisation | 53% | 48% | 55% | 51% | −4% |
Injection bed utilisation | 29% | 30% | 40% | 37% | 28% |
Number of Anti-VEGF injections | 169 | 172 | 218 | 215 | 27% |
Costing | £151,760 | £153,963 | £192,902 | £190,200 | 25% |
Revenue | £207,494 | £207,494 | £260,809 | £251,664 | 21% |
Surplus | £55,735 | £53,532 | £67,906 | £61,464 | 10% |